Demystifying Jazz Pharmaceuticals: Insights From 15 Analyst Reviews
Portfolio Pulse from Benzinga Insights
In the past three months, 15 analysts have reviewed Jazz Pharmaceuticals (NASDAQ:JAZZ), showing a mix of bullish to bearish sentiments. The average 12-month price target is $195.73, up 1.35% from the previous $193.12. Analyst actions include maintaining, raising, and lowering ratings and price targets, reflecting responses to market dynamics and company performance. Jazz Pharmaceuticals, an Ireland-based biopharmaceutical company, focuses on sleeping disorders and oncology, with nine approved drugs. Financially, it has shown a revenue growth of 4.1% as of December 31, 2023, but lags in ROE and excels in net margin and ROA.
May 02, 2024 | 2:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Jazz Pharmaceuticals has received mixed reviews from analysts, with an updated average 12-month price target of $195.73. The company's financial performance shows positive revenue growth and a strong net margin, although it faces challenges in ROE.
The mixed analyst sentiments with a slight increase in the average price target suggest a cautiously optimistic outlook for JAZZ. The company's solid financial performance, particularly in revenue growth and net margin, supports a positive short-term impact on the stock price. However, the challenges in ROE might temper the enthusiasm slightly, hence the score of 1, indicating a likely increase in stock price but with caution.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100